Skip to content

Arbutus Biopharma Corp

ABUS

CIK 0001447028

← back to feed
Revenue (TTM)
192.16M
+128.2% YoY Q1 May 2026
Net Income (TTM)
139.95M
+52.1% YoY Q1 May 2026
EPS Diluted (TTM)
0.71
+55.3% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
70.8%
Q1 May 2026
Net Margin
72.8%
Q1 May 2026
Free Cash Flow (TTM)
−68.38M
Q1 May 2026
Cash
23.71M
Q1 May 2026
Total Debt
0
Q1 May 2026
Shares Outstanding
197.54M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings